Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain

References

• Allison DB, Loebel AD, Lombardo I, Romano SJ, Siu CO. 2009. Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? Psychiatry Res 170(2–3):172–176.
   PubMed Web of Science ®Google Scholar
• Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM, et al. 2004. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65(10):1335–1342.
   PubMed Web of Science ®Google Scholar
• Baptista T, Rangel N, El Fakih Y, Uzcategui E, Galeazzi T, Beaulieu S, et al. 2009. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry 42(1):14–19.
   PubMed Web of Science ®Google Scholar
• Barnett AG, van der Pols JC, Dobson AJ. 2005. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 34(1):215–220.
   PubMed Web of Science ®Google Scholar
• Baron DN. 1956. Hypothyroidism; its aetiology and relation to hypometabolism, hypercholesterolaemia, and increase in body-weight. Lancet 271(6937):277–281.
   PubMedGoogle Scholar
• Barrett E, Blonde L, Clement S, Davis J, Devlin J, Kane J, et al. 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2): 596–601.
   PubMed Web of Science ®Google Scholar
• Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. 2001. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62(4):231–238.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 57 289–300.
   Google Scholar
• Bland JM, Altman DG. 1994. Regression towards the mean. Br Med J 308(6942):1499.
   PubMedGoogle Scholar
• Bossuyt PM, Reitsma JB. 2003. The STARD initiative. Standards for Reporting of diagnostic Accuracy. Lancet 361(9351):71.
   PubMedGoogle Scholar
• Brandl EJ, Frydrychowicz C, Tiwari AK, Lett TA, Kitzrow W, Buttner S, et al. 2012. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Prog Neuropsychopharmacol Biol Psychiatry 38(2):134–141.
   PubMed Web of Science ®Google Scholar
• Buchholz S, Morrow AF, Coleman PL. 2008. Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Intern Med J 38(7):602–606.
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. 2013. Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. J Psychopharmacol 27(4):358–365.
   PubMed Web of Science ®Google Scholar
• Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, et al. 2006. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55(10):2688–2697.
   PubMed Web of Science ®Google Scholar
• Devlin AM, Ngai YF, Ronsley R, Panagiotopoulos C. 2012. Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics. Transl Psychiatry 2:e71.
   Web of Science ®Google Scholar
• Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, et al. 2003. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 64(12): 1436–1439.
   PubMed Web of Science ®Google Scholar
• Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, Nicoletti G, Giugliano D. 2002. Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 87(8):3864–3866.
   PubMed Web of Science ®Google Scholar
• Febbraio MA, Rose-John S, Pedersen BK. 2010. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?Clin Pharmacol Ther 87(4):396–398.
   PubMed Web of Science ®Google Scholar
• Fernandez-Egea E, Bernardo M, Parellada E, Justicia A, Garcia-Rizo C, Esmatjes E, et al. 2008. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res 103(1–3):110–113.
   PubMed Web of Science ®Google Scholar
• Ganguli R. 2007. Behavioral therapy for weight loss in patients with schizophrenia. J Clin Psychiatry 68(Suppl 4):19–25.
   PubMedGoogle Scholar
• Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC, et al. 2009. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 43(6):620–626.
   PubMed Web of Science ®Google Scholar
• Greenman Y, Tordjman K, Stern N. 1998. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxford) 48(5):547–553.
   PubMed Web of Science ®Google Scholar
• Grunder G, Wetzel H, Schlosser R, Anghelescu I, Hillert A, Lange K, et al. 1999. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 45(1): 89–97.
   PubMed Web of Science ®Google Scholar
• Hoogwerf BJ, Nuttall FQ. 1984. Long-term weight regulation in treated hyperthyroid and hypothyroid subjects. Am J Med 76(6):963–970.
   PubMed Web of Science ®Google Scholar
• Hummer M, Huber J. 2004. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 20(2): 189–197.
   PubMed Web of Science ®Google Scholar
• Jiang L, Lindpaintner K, Li HF, Gu NF, Langen H, He L, Fountoulakis M. 2003. Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids 25(1): 49–57.
   PubMed Web of Science ®Google Scholar
• Khan A, Macaluso M, McHale R, Dahmen M, Girrens K, Ali F. 2010. The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. J Psychiatr Pract 16:289–296.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. 2001. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62(2): 92–100.
   PubMed Web of Science ®Google Scholar
• Kirk SL, Cahir M, Reynolds GP. 2006. Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus. J Psychopharmacol 20(4):577–579.
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3):519–526.
   PubMed Web of Science ®Google Scholar
• Lakhan SE. 2006. Schizophrenia proteomics: biomarkers on the path to laboratory medicine?Diagn Pathol 1:11.
   PubMed Web of Science ®Google Scholar
• Lazar MA. 2005. How obesity causes diabetes: not a tall tale. Science 307(5708):373–375.
   PubMed Web of Science ®Google Scholar
• Lebovitz HE. 2003. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q 74(3):277–290.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 353(12):1209–1223.
   PubMed Web of Science ®Google Scholar
• Liu M, Doi T, Shen L, Woods SC, Seeley RJ, Zheng S, et al. 2001. Intestinal satiety protein apolipoprotein AIV is synthesized and regulated in rat hypothalamus. Am J Physiol Regul Integr Comp Physiol 280(5):R1382–1387.
   Web of Science ®Google Scholar
• Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. 1995. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29(2):141–152.
   PubMed Web of Science ®Google Scholar
• McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. 2004. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65(Suppl 18):47–56.
   PubMedGoogle Scholar
• Mukherjee S, Schnur DB, Reddy R. 1989. Family history of type 2 diabetes in schizophrenic patients. Lancet 1(8636):495.
   PubMed Web of Science ®Google Scholar
• Narula PK, Rehan HS, Unni KE, Gupta N. 2010. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 118(1–3):218–223.
   PubMed Web of Science ®Google Scholar
• Naudin J, Mege JL, Azorin JM, Dassa D. 1996. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 20(3): 269–273.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. 2006. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 67(11):e16.
   Web of Science ®Google Scholar
• Newcomer JW. 2007. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68(Suppl 4):8–13.
   PubMed Web of Science ®Google Scholar
• Nyrnes A, Jorde R, Sundsfjord J. 2006. Serum TSH is positively associated with BMI. Int J Obes (London) 30(1):100–105.
   PubMed Web of Science ®Google Scholar
• Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. 2007. The epidemiology of obesity. Gastroenterology 132(6):2087–2102.
   PubMed Web of Science ®Google Scholar
• Palacioz K. 2004. Risperdal (risperidone) for bipolar mania. Therapeutic Research Center. Pharmacist's Letter/Prescriber's Letter (20):200109.
   Google Scholar
• Qin X, Tso P. 2005. The role of apolipoprotein AIV on the control of food intake. Curr Drug Targets 6(2):145–151.
   PubMed Web of Science ®Google Scholar
• Roerig JL, Steffen KJ, Mitchell JE. 2011. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 25(12):1035–1059.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Collins P, Thakore JH. 2003. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160(2):284–289.
   PubMed Web of Science ®Google Scholar
• Saddichha S, Ameen S, Akhtar S. 2008. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol 28(1):27–31.
   PubMed Web of Science ®Google Scholar
• Sasayama D, Wakabayashi C, Hori H, Teraishi T, Hattori K, Ota M, et al. 2011. Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients. J Psychiatr Res 45(11):1439–1444.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, De Hert MA. 2007. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 33(3):169–175.
   PubMed Web of Science ®Google Scholar
• Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, et al. 2012. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 17(5):494–502.
   PubMed Web of Science ®Google Scholar
• Souza RP, Tiwari AK, Chowdhury NI, Ceddia RB, Lieberman JA, Meltzer HY, et al. 2012. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. J Psychiatr Res 46(4):462–468.
   PubMed Web of Science ®Google Scholar
• Szkudlinski MW, Fremont V, Ronin C, Weintraub BD. 2002. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev 82(2):473–502.
   PubMed Web of Science ®Google Scholar
• Thakore JH. 2004. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 47:S76–79.
   Google Scholar
• Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 2009. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690):620–627.
   PubMed Web of Science ®Google Scholar
• Tuomisto J, Mannisto P. 1985. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 37(3):249–332.
   PubMed Web of Science ®Google Scholar
• van Neck JW, Berghout EM, Vinter-Jensen L, Groffen CA, Cingel V, Dits NF, et al. 2000. The effect of epidermal growth factor and IGF-I infusion on hepatic and renal expression of the IGF-system in adult female rats. J Endocrinol 165(1): 115–122.
   PubMed Web of Science ®Google Scholar
• Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. 2001. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9(7):414–417.
   PubMedGoogle Scholar
• Wetzel H, Wiesner J, Hiemke C, Benkert O. 1994. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers. J Psychiatr Res 28(5):461–473.
   PubMed Web of Science ®Google Scholar
• Wheatcroft SB, Kearney MT. 2009. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab 20(4):153–162.
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Pierre JM, Erhart SM, Boyd JA. 2003. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin North Am 26(1):165–190.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wan C, Li H, Zhu H, La Y, Xi Z, et al. 2006. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 78(11):3571–3576.
   PubMed Web of Science ®Google Scholar